Siarot, Jurhamae S.
HRN: 29-31-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/20/2026
CO-AMOXICLAV 625MG (TAB)
07/20/2026
07/27/2026
PO
625mg
BID X 7 Days
S/P NSVD With RMLE; Thinly MSAF
Checking Final Appropriateness
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes